Jeff Quillen, partner and co-chair of Foley Hoag’s Life Sciences Industry Group, was recently quoted in a
C&EN article about the evolving biotech financing environment, highlighting the growing difficulties faced by emerging companies in securing capital.
“It’s really hard for emerging companies to raise capital,” Quillen said, emphasizing the particular challenges faced by young, inexperienced, or underrepresented founders. Quillen also pointed to recent interest rate cuts by the Federal Reserve as a potential catalyst for change, suggesting that lowered rates could help unlock more funding opportunities.
Read the full article.
